Intended for healthcare professionals


US drug maker sues to force Ireland to offer expensive Duchenne’s treatment

BMJ 2017; 358 doi: (Published 15 September 2017) Cite this as: BMJ 2017;358:j4302
  1. Owen Dyer
  1. Montreal

The American pharmaceutical firm PTC Therapeutics is suing Ireland’s Health Service Executive (HSE) over its decision not to fund drugs for two boys with Duchenne muscular dystrophy (DMD).

PTC’s drug, ataluren (Translarna), has been approved by the European Medicines Agency (EMA) to treat the nonsense mutation form of DMD in children aged over 5. This condition affects two boys over 5 in the Republic of Ireland and one in Northern Ireland. The boy in Northern Ireland is receiving the drug and has benefited, according to his parents. The two boys …

View Full Text

Log in

Log in through your institution


* For online subscription